Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.cgh.2006.03.025
DC FieldValue
dc.titleEndoscopic Screening for Gastric Cancer
dc.contributor.authorDan, Y.Y.
dc.contributor.authorYeoh, K.G.
dc.contributor.authorSo, J.B.Y.
dc.date.accessioned2011-09-27T05:16:09Z
dc.date.available2011-09-27T05:16:09Z
dc.date.issued2006
dc.identifier.citationDan, Y.Y., Yeoh, K.G., So, J.B.Y. (2006). Endoscopic Screening for Gastric Cancer. Clinical Gastroenterology and Hepatology 4 (6) : 709-716. ScholarBank@NUS Repository. https://doi.org/10.1016/j.cgh.2006.03.025
dc.identifier.issn15423565
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/26835
dc.description.abstractBackground & Aims: Population endoscopic screening for gastric cancer is generally deemed not to be cost-effective except in Japan, where its prevalence is very high. However, in the absence of screening, patients present with advanced disease, and prognosis is poor. We conducted a cost utility analysis to determine whether endoscopic screening for stomach cancer in intermediate-risk population would be cost-effective and to better define the high-risk groups in the population who would benefit from such strategy. Methods: Cost-effectiveness analysis was performed by using a Markov Model. Simulation was performed on Singapore (intermediate-risk) population and various high-risk subgroups. Comparison was made between 2-yearly endoscopic mass screening program versus no screening. Data sources were extracted from relevant studies published from 1980-2004 identified via systematic PUBMED search. Main outcome measures were deaths caused by stomach cancer averted, cost per life saved, and incremental cost-effectiveness ratio expressed as cost per quality-adjusted life year (QALY) saved. Results: Screening of high-risk group of Chinese men (age-standardized rate, 25.9/100,000) from 50-70 years old is highly cost-effective, with cost benefit of United States $26,836 per QALY. Screening this cohort of 199,000 subjects prevents 743 stomach cancer deaths and saves 8234 absolute life years. Cost of averting 1 cancer death is United States $247,600. Cost-effectiveness was most sensitive to incidence of stomach cancer and cost of screening endoscopy. Conclusions: Screening of stomach cancer in moderate to high-risk population subgroups is cost-effective. Targeted screening strategies for stomach cancer should be explored. © 2006 American Gastroenterological Association.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.cgh.2006.03.025
dc.sourceScopus
dc.typeArticle
dc.contributor.departmentMEDICINE
dc.description.doi10.1016/j.cgh.2006.03.025
dc.description.sourcetitleClinical Gastroenterology and Hepatology
dc.description.volume4
dc.description.issue6
dc.description.page709-716
dc.identifier.isiut000238350500010
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

123
checked on Apr 10, 2021

WEB OF SCIENCETM
Citations

118
checked on Apr 2, 2021

Page view(s)

185
checked on Mar 31, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.